Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

Clearside Biomedical, Inc. (Nasdaq: CLSD), a pioneering biopharmaceutical company based in Alpharetta, Georgia, is set to participate in a fireside chat on May 27, 2025, during the Stifel 2025 Virtual Ophthalmology Forum at 9:00 a.m. ET. The event will provide an opportunity for Clearside's management to discuss its innovative approach to delivering therapies to the back of the eye via the suprachoroidal space (SCS®) — a technique aimed at enhancing patient outcomes in ophthalmic treatments. Those interested can access the live and archived webcast on Clearside's website under the Investors section in the Events and Presentations area, where it will remain available for three months.

Clearside’s unique SCS injection platform, which utilizes the patented SCS Microinjector®, allows for a repeatable, in-office, non-surgical procedure for the precise delivery of various therapeutic agents to the macula, retina, or choroid regions of the eye. This targeted approach can potentially preserve and improve vision in patients suffering from sight-threatening conditions.

The company is actively advancing its pipeline of small molecule product candidates for use with the SCS Microinjector, with its leading program, CLS-AX (axitinib injectable suspension), currently being developed for the treatment of neovascular age-related macular degeneration (wet AMD). Plans for a Phase 3 clinical program for this indication are underway. Additionally, Clearside is also exploring other small molecules for the long-acting treatment of geographic atrophy (GA).

Having already developed and achieved approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, Clearside continues to expand its impact on the field of ocular medicine through strategic partnerships and innovations. For further details, visit clearsidebio.com or follow them on social media platforms like LinkedIn and X.

As Clearside Biomedical, Inc. (Nasdaq: CLSD) gears up for its participation in the Stifel 2025 Virtual Ophthalmology Forum, investors should take this opportunity to evaluate the company’s growth potential and market position. The firm specializes in innovative therapies delivered to the back of the eye through its proprietary suprachoroidal space (SCS) injection platform. This technology is gaining recognition for its potential to vastly improve patient outcomes in treating sight-threatening diseases.

Currently, Clearside’s lead candidate, CLS-AX, is under development for neovascular age-related macular degeneration (wet AMD)—a major ocular condition affecting millions. The company’s upcoming Phase 3 program signifies a critical step that could boost its profile and share value. As investors consider Clearside, it's important to note the commercial success of its approved product, XIPERE, which is now available in the U.S. This solidifies Clearside's credibility and its ability to bring ophthalmic innovations to market.

Participation in the Stifel forum provides Clearside's management with a platform to share key updates and strategic plans that could influence investor sentiment positively. Market dynamics also favor innovations in ophthalmology, with an increasing prevalence of age-related eye conditions in an aging global population, heightening demand for new therapies.

Investors should closely monitor the developments shared during the forum, especially relating to CLS-AX’s trajectory and any partnership opportunities that could further leverage Clearside’s SCS platform. Given the potential for breakthrough innovations and the firm’s existing pipeline, Clearside Biomedical presents an enticing prospect for investors looking to capitalize on advancements in ophthalmic treatments. While risks in drug development remain, strategic engagement at forums like Stifel's can showcase management's vision, reinforcing investor confidence.